Key Takeaways:
A securities class action lawsuit was filed against Boston Scientific Corporation (NYSE: BSX) on behalf of investors who purchased stock between July 23, 2025, and Feb. 3, 2026, following a sharp drop in the company’s share price.
Multiple law firms, including Bernstein Liebhard LLP and Faruqi & Faruqi, LLP, announced the lawsuit, which alleges that the company made false and misleading statements regarding its U.S. Electrophysiology (EP) segment. The deadline for investors to seek the role of lead plaintiff is May 4, 2026.
The complaint alleges that Boston Scientific failed to disclose that its U.S. EP segment’s growth rate was unsustainable and that it was facing increased competition. On Feb. 4, 2026, the company announced disappointing fourth-quarter 2025 results and issued guidance for 2026 that fell below expectations, causing the stock to fall $16.12, or 17.6 percent, to close at $75.50 per share.
The lawsuit argues that investors were harmed by the company's alleged misrepresentations, which kept the stock price artificially inflated. The subsequent stock drop after the negative news was revealed is the basis for the claimed damages.
The central claim of the lawsuit is that Boston Scientific's management was aware of the headwinds facing the EP segment but continued to project confidence to investors. The complaint highlights previous management assertions of having a "very good understanding of what competition we will face and in what time frame," which plaintiffs claim was contradicted by the poor results and outlook.
The legal filings seek to recover damages for investors who purchased Boston Scientific common stock during the class period. Any member of the putative class may move the court to serve as lead plaintiff.
The decline puts the stock at its lowest level since the third quarter of 2025. Investors will be watching for the company's response to the allegations and any further updates on the class action lawsuit as the lead plaintiff deadline approaches.
This article is for informational purposes only and does not constitute investment advice.
